Taho Pharmaceuticals (ROCO:6467) Stock Based Compensation: NT$12.65 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6467 Taho Pharmaceuticals Ltd ROCO:6467
33 GF Score
Price NT$113.50
! 2 Warning Signs
View Full Analysis

What is Taho Pharmaceuticals Stock Based Compensation?

Taho Pharmaceuticals ROCO:6467 -0.87% 33 Stock Based Compensation is NT$12.65 Mil as of Dec. 2025. GuruFocus rates ROCO:6467 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Taho Pharmaceuticals's Stock Based Compensation for the six months ended in Dec. 2025 was NT$12.62 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was NT$12.65 Mil.

Taho Pharmaceuticals Stock Based Compensation Related Terms

Taho Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Taho Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taho Pharmaceuticals Stock Based Compensation Chart

Taho Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 0.12 -0.15 0.35 0.04 12.65

Taho Pharmaceuticals Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 -0.02 0.05 0.03 12.62
ROCO:6467
33GF Score
Taho Pharmaceuticals Ltd ROCO:6467
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taho Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$12.65 Mil.

What does a Stock Based Compensation of NT$12.65 Mil mean?
Taho Pharmaceuticals (ROCO:6467) has a Stock Based Compensation of NT$12.65 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Taho Pharmaceuticals and its competitors.
Is Taho Pharmaceuticals' Stock Based Compensation too high?
Taho Pharmaceuticals' current Stock Based Compensation is NT$12.65 Mil. Overall, Taho Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' Stock Based Compensation compare to ZTS?
Taho Pharmaceuticals' Stock Based Compensation of NT$12.65 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Taho Pharmaceuticals and its competitors. Taho Pharmaceuticals's current Stock Based Compensation is NT$12.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current Stock Based Compensation of NT$12.65 Mil. The current Stock Based Compensation is NT$12.65 Mil. Taho Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current Stock Based Compensation is NT$12.65 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Taho Pharmaceuticals Business Description

Address No. 550, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
33GF Score

Get the complete analysis for ROCO:6467

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$113.50
Price